United Therapeutics (NASDAQ:UTHR) COO Michael Benkowitz Sells 14,625 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 14,625 shares of the stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $464.66, for a total transaction of $6,795,652.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Michael Benkowitz also recently made the following trade(s):

• On Tuesday, January 20th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The shares were sold at an average price of $464.66, for a total transaction of $3,659,197.50.
• On Monday, January 26th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $471.91, for a total transaction of $10,617,975.00.
• On Monday, January 12th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $479.51, for a total transaction of $10,788,975.00.
• On Monday, January 5th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The stock was sold at an average price of $487.38, for a total transaction of $3,838,117.50.
• On Monday, January 5th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The stock was sold at an average price of $487.38, for a total value of $7,127,932.50.
• On Monday, December 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $502.79, for a total value of $11,312,775.00.
• On Monday, December 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $514.35, for a total transaction of $11,572,875.00.
• On Monday, December 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $496.30, for a total value of $11,166,750.00.
• On Monday, December 8th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $478.58, for a total transaction of $10,768,050.00.
• On Monday, December 1st, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $479.91, for a total value of $10,797,975.00.

United Therapeutics Stock Down 2.0%

NASDAQ:UTHR traded down $9.48 during trading hours on Wednesday, hitting $467.30. 274,140 shares of the stock traded hands, compared to its average volume of 357,474. The company has a market cap of $20.12 billion, a price-to-earnings ratio of 17.71, a price-to-earnings-growth ratio of 2.54 and a beta of 0.84. The stock has a 50 day moving average price of $487.69 and a 200 day moving average price of $418.26. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $519.99.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm had revenue of $799.50 million for the quarter, compared to the consensus estimate of $812.87 million. During the same quarter in the previous year, the company posted $6.39 EPS. The company’s revenue for the quarter was up 6.8% compared to the same quarter last year. Equities analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Institutional Trading of United Therapeutics

Hedge funds have recently bought and sold shares of the company. Chung Wu Investment Group LLC bought a new position in United Therapeutics during the second quarter worth about $29,000. WealthCollab LLC raised its stake in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. increased its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares in the last quarter. Wilmington Savings Fund Society FSB lifted its holdings in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares in the last quarter. Finally, Abich Financial Wealth Management LLC acquired a new position in United Therapeutics in the 3rd quarter worth $44,000. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Wells Fargo & Company raised their target price on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. HC Wainwright boosted their price objective on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Jefferies Financial Group restated a “buy” rating and issued a $575.00 price target on shares of United Therapeutics in a research report on Wednesday, November 19th. Finally, Morgan Stanley set a $447.00 target price on United Therapeutics in a report on Wednesday, October 29th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $509.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.